Current and emerging tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia in young adults.

Although we do not have sufficient data, young adult population has a special importance for TKI treatment. Clinical features, efficacy of treatments and specific conditions in this age group should attract more attention of clinicians and more intensive studies should be conducted in the future.